Site Operations Survey Highlights Slow Adoption of Risk-Based Monitoring
ACRP and CenterWatch released a collaborative benchmarking report on clinical research site performance
The Association of Clinical Research Professionals (ACRP) and CenterWatch released a collaborative benchmarking report on clinical research site performance as a result of the largest independent, unbiased survey of site leadership.
The data, available in two separate reports—one comparing smaller sites to average site metrics, and one comparing larger sites to average—is available at www.acrpnet.org/sitebenchmarking and http://store.centerwatch.com/p-433-2014-financial-and-operating-benchmark-reports.aspx
Highlights include:
- 23% of sites have taken no training action to prepare for Risk-Based Monitoring;
- 45% of sites are not planning for, or implementing, Risk-Based Monitoring; and
- 36% of sites plan to increase staff at the coordinator level in 2015.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
